ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration

Guan, Rui; Lyu, Qiong; Lin, Anqi; Liang, Junyi; Ding, Weimin; Cao, Manming; Luo, Peng*; Zhang, Jian*南方医科大学
Frontiers in Oncology2021-6-23DOI: 10.3389/fonc.2021.670927
6被引4阅读
引用收藏
分享

摘要

Age is a potential predictive marker for the prognosis of cancer patients treated with immune checkpoint inhibitors (ICIs), but the appropriate age cutoff point is still controversial. We aimed to explore the influence of different age cutoff points on the prediction of prognosis for patients receiving ICIs and explore the mechanism underlying the appropriate age cutoff point from the aspects of gene mutation and expression, immune cell infiltration and so on. We applied cutoff points of 50, 55, 60, 65, 70, and 75 years old to divide 1660 patients from the Memorial Sloan-Kettering Cancer Center (MSKCC) immunotherapy cohort into older and younger groups and performed survival analysis of the six subgroups. The results showed that older patients had better survival than younger patients in accordance with the cutoff point of 50 years old [median overall survival (OS) (95% CI): 13.0 (10.5-15.5) months vs. 20.0 (16.7-23.3) months; p=0.002; unadjusted hazard ratio (HR) (95% CI): 0.77 (0.65-0.91)], whereas no significant difference was observed with other cutoff points. Further analysis of The Cancer Genome Atlas (TCGA) database and the MSKCC immunotherapy cohort data showed that the tumor mutation burden (TMB), neoantigen load (NAL), DNA damage response and repair (DDR) pathway mutation status, mutation frequencies of most genes (except IDH1, BRAF and ATRX), the expression of most immune-related genes and the degree of infiltration of most immune cells (such as CD8+ T cells and M1 macrophages) were higher in the elderly group (aged >= 50 years).

学科与关键词

关键词
pan-cancerICIagepredictive markersprognosis
相关
加载中…
  • Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study
    Xiao, Lushan; Liao, Yanxia; Wang, Jiaren; Li, Qimei; Zhu, Hongbo; Hong, Chang; Li, Ruining; He, Jingzhe; Cui, Hao*; Dong, Hanzhi*; Zeng, Lin*; Liu, Li*Cancer Immunology, Immunotherapy, 2023, 72(7): 2299-2308.被引 2
  • Pan-cancer transcriptomic analysis identified six classes of immunosenescence genes revealed molecular links between aging, immune system and cancer
    Wang, Xinyue; Guo, Shuang; Zhou, Hanxiao; Sun, Yue; Gan, Jing; Zhang, Yakun; Zheng, Wen; Zhang, Caiyu; Wang, Peng; Zhi, Hui; Gao, Yue; Chen, Xiaofeng*; Ning, Shangwei*GENES AND IMMUNITY, 2023, 24(2): 81-91.被引 2
  • Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts
    Zhang, Liuchao; Wang, Yuanyuan; Wang, Liuying; Wang, Meng; Li, Shuang; He, Jia; Ji, Jianxin; Li, Kang*; Cao, Lei*Journal of Molecular Medicine, 2024, 102(1): 69-79.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-06-23
卷期
第 11 卷
页码
670927
DOI
10.3389/fonc.2021.670927
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2018A030313846]

作者

  • G

    Guan, Rui (第一作者)

    southern med univ

  • L

    Lyu, Qiong

    southern med univ

查看全部 8 位作者收起作者
  • L

    Lin, Anqi

    southern med univ

  • L

    Liang, Junyi

    southern med univ

  • D

    Ding, Weimin

    southern med univ

  • C

    Cao, Manming

    southern med univ

  • L

    Luo, Peng (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417